TABLE 1.
Antimicrobial susceptibility and carbapenemase confirmation test results for clinical isolate K. pneumoniae 181E2 (KPC-39), E. coli TOP10 transformants, and E. coli TOP10
| Antibiotic or confirmation test | Antibiotic MIC (mg/liter) or confirmation test result |
|||
|---|---|---|---|---|
| K. pneumoniae 181E2 (KPC-39) | E. coli TOP10 (pTOPO-KPC-3) | E. coli TOP10 (pTOPO-KPC-39) | E. coli TOP10 | |
| Antibiotics | ||||
| Amoxicillina | >256 | >256 | >256 | 6 |
| Amoxicillin-clavulanatea | 24 | 48 | 24 | 6 |
| Cefiximea | 6 | 12 | 4 | 0.38 |
| Cefotaximea | 4 | >32 | 2 | 0.064 |
| CAZa | >256 | >256 | >256 | 0.125 |
| CAZ-AVIa | 12 | 0.75 | 4 | 0.125 |
| Cefepimea | 4 | 6 | 2 | 0.0064 |
| Aztreonama | >256 | >256 | >256 | 0.047 |
| Ertapenema | 0.25 | 1 | 0.094 | 0.004 |
| Imipenema | 0.5 | 8 | 1 | 0.25 |
| Meropenema | 0.19 | 3 | 0.094 | 0.032 |
| Imipenem plus relebactamb | 0.12 | |||
| Meropenem plus vaborbactamb | <0.06 | |||
| Cefiderocolb | 0.5 | |||
| Fosfomycinb | <16 | |||
| Tigecyclineb | <0.5 | |||
| Co-trimoxazoleb | 0.125 | |||
| Colistinb | <0.5 | |||
| Amikacinb | <2 | |||
| Tobramycinb | <0.5 | |||
| Ciprofloxacinb | >16 | |||
| Nitrofurantoinb | <8 | |||
| Carbapenemase confirmation tests | ||||
| Biochemicalc | ||||
| CarbaNP test | − | + | − | NDd |
| β CARBA test | − | + | − | ND |
| MBT Star-Carba IVD kit | − | + | − | ND |
| LFIA (NG-Test CARBA-5)e | + | ND | ND | ND |
| Molecular (Xpert Carba-R)f | + | ND | ND | ND |
a
MIC results obtained using Etests (bioMérieux).
b
MIC results obtained by broth microdilution (Sensititre; Thermo Fisher Scientific).
c
CarbaNP test (30), β-CARBA test (Bio-Rad, Marne-la-Coquette, France), and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) MBT Star-Carba IVD kit (Bruker Daltonics, Bremen, Germany).
d
ND, not determined.
e
LFIA (NG-Test Carba 5) (NG Biotech, Guipry, France).
f
Xpert Carba-R PCR assay (Cepheid, Maurens-Scopont, France).